Navigation Links
Lupin Announces Launch of Generic KEPPRA XR® Tablets
Date:9/14/2011

BALTIMORE, Sept. 14, 2011 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. (LPI) announced today that the U.S. Food and Drug Administration (FDA) has granted final approval for the Company's Abbreviated New Drug Application (ANDA) to market a generic version of UCB's KEPPRA XR tablets.  Commercial shipment of the product has commenced.

Lupin's levetiracetam 500 mg and 750 mg extended-release tablets are the AB-rated generic equivalent of KEPPRA XR, an antiepileptic drug indicated for adjunctive therapy in the treatment of partial onset seizures in patients >/= 16 years of age with epilepsy.  KEPPRA XR tablets had annual sales of approximately $161 million for the twelve months ended June 2011 based on IMS Health sales data.

About Lupin

Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs.  The Company today has significant market share in Cardiovasculars, Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs in addition holding global leadership positions in the Anti-TB and Cephalosporins space.

Today, Lupin is the 5th largest and fastest growing generics player in the US (by prescriptions), the only Asian company to achieve that distinction.  The company is also the fastest growing top 10 pharmaceutical player in India, Japan and South Africa. (IMS Health)

For the financial year ended March 2011, Lupin's Consolidated Revenues and Profit after Tax were Rs. 57,068 million (USD 1.28 Billion) and Rs. 8,626 million (USD 193 million) respectively.  Please visit http://www.lupinworld.com for more information about Lupin Ltd.

Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited.  Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies.  For more information, visit http://www.lupinpharmaceuticals.com.

Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Many of these risks, uncertainties and other factors include failure of clinical trials, delays in development, registration and product approvals, changes in the competitive environment, increased government control over pricing, fluctuations in the capital and foreign exchange markets and the ability to maintain patent and other intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release

*Keppra XR® is a registered trademark of the UCB Group of Companies.

For More Information:
Contact: Edith St-Hilaire
Director of Marketing
(410) 576-2000
esthilaire@lupinusa.com


'/>"/>
SOURCE Lupin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lupin Receives Final Approval to Market Generic Ultram® ER
2. Eli Lilly India and Lupin Announce Strategic Collaboration to Help Fight the Battle Against Diabetes
3. Lupin Launches Additional Strengths of Generic Lotrel® Capsules
4. Lupin Announces Launch of Generic Levaquin® Tablets
5. HDMA Honors Lupin with DIANA Award for Best Overall Generic Manufacturer
6. Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations
7. Lupin Expands Branded Play
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at UBS Global Life Sciences Conference
9. Main Street Capital Announces New Portfolio Investment
10. Boston Scientific Names Michael F. Mahoney as Company President, Announces CEO Transition Plan
11. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... Flight Network and PeaceHealth Oregon Network announced they renewed a ... efficiency for patients at hospitals in Eugene ... , and Florence, Oregon , who ... work collaboratively to move patients who require the highest level ... emergency exists. PeaceHealth ...
(Date:8/1/2017)...   CerSci Therapeutics , a non-opioid drug development ... has received notice from the National Institute on Drug ... that it has been awarded a Direct-to-Phase II Small ... 2017 with an additional $1,000,000 to follow in 2018. ... of their lead non-opioid drug candidate CT-044 to the ...
(Date:7/31/2017)... , July 31, 2017 Three Tru-D SmartUVC ... South Korea . Tru-D, short for "Total Room Ultraviolet ... operating rooms after an environmental services (ES) professional cleans the area with ... ... "Although the BAACH ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... Director of its Sienna Plantation facility. , “We are pleased to announce Dr. ... Dr. Michael (Derek) Caraway, Area Medical Director of First Choice Emergency Room – North ...
(Date:8/16/2017)... ... ... Break Every Chain”: an inspirational story for those shackled by the chains of a broken ... Shivers, a writer and a woman of great faith and wisdom. She is a ... She was born and raised in Vero Beach, Florida and has dedicated her life and ...
(Date:8/15/2017)... Buffalo, NY (PRWEB) , ... August 15, 2017 , ... ... as maintenance treatment for multiple myeloma has been completed, with the team’s findings now ... Philip L. McCarthy, MD , Director of the Blood and Marrow Transplant Program at ...
(Date:8/15/2017)... ... August 15, 2017 , ... Progressive Dental, a leading dental ... the 2017 Fast 50 list of Fastest Growing Companies in Tampa Bay. The Tampa ... who has shown three consecutive years of growth. For this year’s award, Progressive Dental ...
(Date:8/15/2017)... ... 2017 , ... Dr. Timothy Davis is now administering two ... This information can be used to develop patient-specific treatment plans for periodontal disease ... tests, named MyPerioPath® and MyPerioID® are offered by OralDNA® Labs, Inc., a subsidiary ...
Breaking Medicine News(10 mins):